Breaking News Bar
updated: 8/2/2013 10:33 AM

Palatine's Acura Pharmaceuticals sees $3.1 million 2Q loss

hello
Success - Article sent! close
 
PRNewswire

Specialty pharmaceutical company Acura Pharmaceuticals, in Palatine, reported a second quarter net loss of $3.1 million primarily due to research and development costs of its anti-abuse technologies.

The net loss for the quarter translated to 7 cents per share, compared to a net loss of $2.2 million or 5 cents per diluted share for the same period in 2012. The costs associated with potential product using the company's Aversion and Impede technologies were $800,000 in the second quarter 2013, compared to $900,000 for the same period in 2012.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Selling, general and administrative expenses were $2.3 million in the second quarter 2013, compared to $1.3 million in the same period last year. Selling expenses for the second quarter 2013 primarily consisted of advertising and marketing activities for Nexafed, a pseudoephedrine tablet that combines effective nasal-congestion relief with a unique technology that disrupts the conversion of pseudoephedrine into the dangerous drug methamphetamine.

As of July 30, 2013, the Company had cash, cash equivalents and marketable securities of $18.4 million and no long term debt.

For the first six months of 2013, Acura reported a net loss of $7.3 million or 16 cents per share, compared to a net loss of $4.5 million or 10 cents per diluted share for the same period in 2012. Research and development expenses were $2.8 million in the six month period, compared to $1.8 million in the same period in 2012. Selling, general and administrative expenses were $4.6 million in the six months ended June 30, 2013, versus $2.7 million in the same period last year.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here